{"DataElement":{"publicId":"4363639","version":"1","preferredName":"Histological Or Cytopathological Diagnosis Refractory Advanced Cancer No Therapy Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has histological or cytopathological diagnosis of an advanced cancer that is refractory to standard therapy or for which no standard therapy exists.","longName":"PT_EC_1001","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4363614","version":"1","preferredName":"Histological Or Cytopathological Diagnosis Refractory Advanced Cancer No Therapy","preferredDefinition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._That portion of the cell contained within the plasma membrane but excluding the nucleus._The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A disease that resists treatment._Cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment._The non-affirmative response to a question._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"4363611v1.0:4363612v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"4363611","version":"1","preferredName":"Histologic Or Cytoplasm Pathology Diagnosis","preferredDefinition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:That portion of the cell contained within the plasma membrane but excluding the nucleus.:The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"4363611v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cytoplasm","conceptCode":"C13226","definition":"That portion of the cell contained within the plasma membrane but excluding the nucleus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathology","conceptCode":"C18189","definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC954610-7A51-5EF5-E040-BB89AD43166E","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"ONEDATA","dateModified":"2014-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4363612","version":"1","preferredName":"Refractory Disease Advanced Malignant Neoplasm No Therapeutic Procedure","preferredDefinition":"A disease that resists treatment.:Cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.:The non-affirmative response to a question.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C39752:C9270:C49487:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Advanced Malignant Neoplasm","conceptCode":"C9270","definition":"A malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC954610-7A64-5EF5-E040-BB89AD43166E","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"ONEDATA","dateModified":"2014-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC954610-7A75-5EF5-E040-BB89AD43166E","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"6/24/14 created for Theradex eligibiliy CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"PT_EC_1001","type":"USED_BY","context":"Theradex"},{"name":"PBTC","type":"USED_BY","context":"PBTC"}],"ReferenceDocuments":[{"name":"Dose escalation phase: Does p","type":"Preferred Question Text","description":"Dose escalation phase: Does patient have histological or cytopathological diagnosis of an advanced cancer that is refractory to standard therapy or for which no standard therapy exists?","url":null,"context":"Theradex"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does patient have histologic verification of a primary CNS tumor at original diagnosis or at relapse? The requirement for histological verification is waived in patients with DIPG (Diffuse Intrinsic Pontine Glioma).","url":null,"context":"PBTC"},{"name":"PBTC-Text3","type":"Alternate Question Text","description":"Does the patient have a histologically confirmed diagnosis of recurrent, progressive or refractory non-brainstem high-grade glioma?","url":null,"context":"PBTC"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Does the patient have a histologically confirmed diagnosis of a primary CNS tumor that is recurrent, progressive or refractory (per protocol definition) to standard therapy?","url":null,"context":"PBTC"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have histologically confirmed measurable or unmeasurable advanced or metastatic breast cancer for which standard curative measures do not exist or are no longer effective?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have histologically confirmed metastatic or unresectable malignancy that is refractory to standard therapy or for which no standard therapy exists and where irinotecan is deemed a reasonable treatment option?","url":null,"context":"Theradex"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"Does the patient have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory?","url":null,"context":"PBTC"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Phase 1: Does patient have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative measures or other therapy definitely capable of extending life expectancy does not exist?","url":null,"context":"Theradex"},{"name":"PBTC_Text5","type":"Alternate Question Text","description":"Does patient have a histologically confirmed diagnosis of HGG, medulloblastoma, CNS embryonal tumor (NOS), ependymoma or ATRT that is recurrent, progressive or refractory?","url":null,"context":"PBTC"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have advanced recurrent or metastatic endometrial cancer?","url":null,"context":"Theradex"},{"name":"PBTC_Text6","type":"Alternate Question Text","description":"Does patient have a histologically confirmed diagnosis of a primary CNS tumor (HGG, medulloblastoma, or DIPG) that is recurrent, progressive or refractory? The requirement for histological verification is waived in patients with DIPG.","url":null,"context":"PBTC"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient have histologically documented metastatic, recurrent, or locally unresectable solid tumors which have progressed after one line of therapy, or for which no curative therapy is available or patients with lymphoma who have received adequate exposure to standard of care therapy and for whom no curative therapy is available?","url":null,"context":"Theradex"},{"name":"PBTC_Text8","type":"Alternate Question Text","description":"Does patient have recurrent or progressive diffuse intrinsic pontine glioma (DIPG), H3K27M-mutant diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma or anaplastic oligodendroglioma?","url":null,"context":"PBTC"},{"name":"PBTC_Text7","type":"Alternate Question Text","description":"Does patient have recurrent or progressive diffuse intrinsic pontine glioma (DIPG), H3K27M-mutant diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma?","url":null,"context":"PBTC"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have recurrent or refractory cancer for which standard curative or palliative measures do not exist or are no longer effective?","url":null,"context":"Theradex"},{"name":"PBTC_Text9","type":"Alternate Question Text","description":"Does patient have newly diagnosed diffuse intrinsic pontine glioma (DIPG)?","url":null,"context":"PBTC"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is registered in the dose escalation, does patient have histologically or cytologically confirmed advanced or metastatic GI cancers with RECIST1.1 measurable disease that has progressed on at least one prior treatment for metastatic disease and for whom FOLFIRI is considered a reasonable treatment option?","url":null,"context":"Theradex"},{"name":"PBTC_Text10","type":"Alternate Question Text","description":"Does the patient have a histologically confirmed diagnosis of ependymoma that is recurrent, progressive or refractory to standard therapy?","url":null,"context":"PBTC"},{"name":"PBTC_Text11","type":"Alternate Question Text","description":"Does the patient have a diagnosis of ependymoma that is recurrent or progressive?","url":null,"context":"PBTC"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have histologically confirmed advanced/metastatic or unresectable solid tumor that is refractory to standard therapy or has relapsed after standard therapy?","url":null,"context":"Theradex"},{"name":"PBTC_Text12","type":"Alternate Question Text","description":"Does patient have a histologically confirmed diagnosis of Glioblastoma multiforme (GBM), Anaplastic astrocytoma, High-grade astrocytoma, NOS, Anaplastic oligodendroglioma, Anaplastic ependymoma (WHO Grade III), Ependymoma WHO Grade II) that is recurrent or progressive?","url":null,"context":"PBTC"},{"name":"PBTC_Text 13","type":"Alternate Question Text","description":"Does patient have recurrent or progressive diffuse intrinsic pontine glioma (DIPG), H3K27M-altered diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma or anaplastic oligodendroglioma?","url":null,"context":"PBTC"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC959792-2973-61C2-E040-BB89AD4370C2","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"GDEEN","dateModified":"2022-09-14","changeDescription":"6/24/14 created for Theradex eligibiliy CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}